Clinical Trials Logo

Nephrosis clinical trials

View clinical trials related to Nephrosis.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05079789 Terminated - Edema Clinical Trials

Amiloride in Nephrotic Syndrome

AMILOR
Start date: June 8, 2020
Phase: Phase 3
Study type: Interventional

The AMILOR study compares treatment of edema in nephrotic syndrome with Amiloride vs. Furosemide.

NCT ID: NCT04950114 Terminated - Kidney Diseases Clinical Trials

An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

Start date: July 27, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD)

NCT ID: NCT04558892 Terminated - Nephrotic Syndrome Clinical Trials

Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.

ENOX-inNS
Start date: October 1, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective is to test the hypothesis that enoxaparin efficacy is reduced in severe nephrotic syndrome. Another purpose is to compare two dosing regimens.

NCT ID: NCT04402580 Terminated - Clinical trials for Nephrotic Syndrome Steroid-Dependent

Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

Anti-CD20 monoclonal antibodies are emerging as the steroid-sparing therapy of choice for nephrotic syndrome. This Randomized Clinical Trial seeks to evaluate whether Rituximab biosimilar maintains drug-free disease remission in patientswith steroid-dependent nephrotic syndrome for 12-24 months and verify its superiority vs. mycophenolate mofetil, the reference standard therapy. The investigators will compare the risk of relapse to test this hypothesis (primary outcome). Secondary objectives will include assessing short- and long-term side-effects and developing specific biomarkers of sensitivity to therapy. Patients will be recruited, treated and followed at IRCCS G Gaslini and IRCCS Bambino Gesù where laboratory studies will be performed at in-site facilities

NCT ID: NCT04387448 Terminated - Diabetes Mellitus Clinical Trials

A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Start date: July 28, 2020
Phase: Phase 2
Study type: Interventional

This is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD).

NCT ID: NCT03878914 Terminated - Clinical trials for Nephrotic Syndrome in Children

Steroid Sensitive Nephrotic Syndrome in Children

Start date: August 6, 2019
Phase: Phase 4
Study type: Interventional

Idiopathic nephrotic syndrome (INS) is one of the most common glomerular pathologies in children and corticosteroid therapy is its most effective treatment. The total duration of treatment ranges anywhere from two to six months, generally about 3 months. The main objective of our study is to test the feasibility of a shorter total duration (two months) of corticosteroid therapy in patients who show a quicker treatment response to the initial treatment.

NCT ID: NCT03703908 Terminated - Clinical trials for Focal Segmental Glomerulosclerosis

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome

NCT ID: NCT03004001 Terminated - Nephrotic Syndrome Clinical Trials

Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

Start date: January 2017
Phase: Phase 2
Study type: Interventional

The study purpose is to determine the hypolipidemic effect of Alirocumab co-administered with atorvastatin on levels of triglyceride-rich lipoproteins and LDL compared to monotherapy with atorvastatin in patients with dyslipidemia secondary to nephrotic syndrome.

NCT ID: NCT02394106 Terminated - Nephrotic Syndrome Clinical Trials

Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome

Start date: July 2015
Phase: Phase 2
Study type: Interventional

Double-blind, two-parallel-arm, placebo-controlled randomized clinical trial testing the superiority of Ofatumumab versus placebo in the treatment of children with DR-INS. Participants will be stratified according to eGFR at enrollment. Eligible participants will enter a 3-months run-in period, during which instructions on urine collection and dipstick readings will be carefully reviewed, compliance assessed and any immunosuppressive therapies withdrawn according to the following schemes: - prednisone will be tapered off by 0.3 mg/kg per week until complete withdrawal; - calcineurin inhibitors and mofetile mycophenolate will be decreased by 50% and withdrawn after 2 additional weeks In order to minimize the risk of complications of uncontrolled INS a treatment with ACE-inhibitor at 6 mg/m2 will be maintained or started in all patients. After run-in period, children will be randomized to the intervention arm (Ofatumumab) or comparator arm (placebo). Randomization will be stratified by eGFR at randomization: ≥90 and <90 ml/min/1.73 m2. All patients will be followed up to 12 months and they will leave the study at time of relapse. Relapse will be defined as uPCR ≥2000 mg/g (≥200 mg/mmol) or ≥ 3+ protein on urine dipstick for 3 consecutive days.

NCT ID: NCT02390362 Terminated - Clinical trials for Steroid Dependent Nephrotic Syndrome

Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome

RAMP
Start date: January 2015
Phase: Phase 3
Study type: Interventional

We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective than MMF in maintaining remission in children with frequent relapsing or steroid dependent nephrotic syndrome who have had one relapse while receiving MMF. We will conduct a randomized study comparing two Rituximab infusions and continued MMF treatment. We plan to enroll 64 to have a comparater group of 58 (29 in each arm).